Use of the Peroxisome Proliferator-Activated Receptor (PPAR)  Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study

By Burstein H.J.  

Breast Cancer Research and Treatment, Vol. 79, Iss. 3, 2003-06 ,pp. : 391-397

Springer Publishing Company

Access to resources Recommend Favorite

The expression and role of peroxisome proliferator-activated receptor α in atherosclerosis

By      

Molecular Medicine Reports, Vol. 7, Iss. 3, 2013-01 ,pp. : 862-868

Spandidos Publications

Access to resources Recommend Favorite

Ligand-Activated Peroxisome Proliferator-Activated Receptor β/δ Modulates Human Endometrial Cancer Cell Survival

By Ma J.   Monsivais D.   Dyson M.   Coon J.   Malpani S.   Ono M.   Zhao H.   Xin H.   Pavone M.   Kim J.   Chakravarti D.   Bulun S.  

Hormones and Cancer, Vol. 4, Iss. 6, 2013-12 ,pp. : 358-370

Springer Publishing Company

Access to resources Recommend Favorite

Peroxisome proliferator-activated receptor γ ligand inhibits cell growth and invasion of human pancreatic cancer cells

By Hashimoto Koji   Ethridge Richard   Evers B.  

International Journal of Gastrointestinal Cancer, Vol. 32, Iss. 1, 2002-08 ,pp. : 7-22

Humana Press, Inc

Access to resources Recommend Favorite

Induction of differentiation and peroxisome proliferator-activated receptor γ expression in colon cancer cell lines by troglitazone

By Kato Masashi   Kusumi Tomomi   Tsuchida Shigeki   Tanaka Masanori   Sasaki Mutsuo   Kudo Hajime  

Journal of Cancer Research and Clinical Oncology, Vol. 130, Iss. 2, 2004-02 ,pp. : 73-79

Springer Publishing Company

Access to resources Recommend Favorite